EHA 2022 | CONPET: KRd consolidation in patients with multiple myeloma with a positive PET/CT after autoHSCT

Jakob Nordberg Nørgaard, PhD, Oslo University Hospital, Oslo, Norway, shares the results of CONPET (NCT03314636), a Phase II study evaluating the impact of carfilzomib-lenalidomide-dexamethasone (KRd) consolidation in patients with multiple myeloma with a positive [18F]-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) after first-line treatment with autologous hematopoietic stem cell transplantation (autoHSCT) and who have achieved a very good partial response (VGPR). Overall, the study found that 33% of patients were FDG PET/CT-positive after autoHSCT, and reported that 33% were converted from FDG PET/CT positivity to negativity after KRd consolidation. In addition, the study showed that MRD assessment and PET/CT were complementary techniques. The study is currently assessing progression-free survival (PFS) and overall survival (OS). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.